A double-blind, placebo-controlled comparative study and open-label extension study to confirm the efficacy and safety of E2020 in subjects with down syndrome having regression symptoms and disabled activities of daily living

Trial Profile

A double-blind, placebo-controlled comparative study and open-label extension study to confirm the efficacy and safety of E2020 in subjects with down syndrome having regression symptoms and disabled activities of daily living

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Donepezil (Primary)
  • Indications Down syndrome
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 21 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 10 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top